ARCH — Arch Biopartners Share News
0.000.00%
Last trade - 00:00- CA$57.06m
- CA$59.79m
- CA$0.28m
Brief: Arch Biopartners Announces Issuance Of U.S. Patent For Dipeptidase-1 Inhibitor Drug
Brief: Arch Provides Interim Update On Phase I Trial For Metablok (Lsalt Peptide)
Brief: Arch Biopartners Announces Start Of Phase I Human Trial For Metablok
Brief: Arch Biopartners Receives Approval To Perform Phase I Clincial Trial For Metablok In Australia
Brief: Arch Biopartners Forms New Subsidiary To Pursue A Phase I Trial In Australia For Metablok (LSALT Peptide)
Brief: Arch Biopartners To Seek Regulatory Guidance From The U.S FDA For AB569
Brief: Arch Biopartners Completes Pre-IND Meeting With FDA On LSALT Peptide
Brief: Arch Biopartners Granted Meeting With FDA For Candidate Drug
Brief: Arch Biopartners Announces Non Brokered Private Placement Financing
Brief: Arch Biopartners closes convertible note financing
Brief: ARCH BIOPARTNERS INITIATES MANUFACTURING PROCESS FOR METABLOK
Brief: Arch Biopartners' GMP nanufacturing of AB569 progresses to final production stage
Brief: Arch Biopartners provides update on GMP manufacturing of AB569
Brief: Arch Biopartners retains market maker, arranges private placement financing
Brief: Arch Biopartners' lead anti-bacterial drug candidate to enter investigator-sponsored Phase I human trial
Brief: Arch Biopartners announces non-brokered private placement financing
Brief: Arch Biopartners announces issuance of U.S. patent for Metablok
Brief: Arch Biopartners to manufacture drug AB569 with Catalent Inhalation
Brief: Arch Biopartners says European Commission designated AB569 as orphan medicinal product in EU